India’s Biggest Problem Is Failure To Use Generics To Improve Health: Britain’s UCL School Of Pharmacy
This article was originally published in PharmAsia News
Executive Summary
India’s biomedical industry faces challenges in organizing clinical trials while multinational firms have lost a series of decisions on patent protections. But it has a silver lining in the generics industry that should be seized to improve health outcomes at home, according to a study by Britain’s UCL School of Pharmacy.